Schwarz Pays $22M To Settle Medicare Fraud Cases

Law360, New York (April 29, 2010, 2:55 PM EDT) -- UCB SA subsidiary Schwarz Pharma Inc. has agreed to pay $22 million to settle allegations that the company did not tell Medicare that two of its drugs were being sold without safety and effectiveness approval.

Schwarz drugs Deponit and Hyoscyamine Sulfate Extended-Release never received full U.S. Food and Drug Administration approval, but Schwarz failed to tell that to the Centers for Medicare and Medicaid Services, the U.S. Department of Justice said Thursday.

The settlement resolves whistleblower lawsuits brought under the False Claims Act in the U.S....
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.